# Neutrophil Gelatinase-associated Lipcalin(NGAL): A Novel Blood Marker for Determining the Risk of Developing Contrast-Induced Nephopathy

> **NCT00693329** · — · COMPLETED · sponsor: **Abbott RDx Cardiometabolic** · enrollment: 260 (estimated)

## Conditions studied

- Cardiovascular Surgery With Coronary Angiography

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT00693329
- **Lead sponsor:** Abbott RDx Cardiometabolic
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2009-06
- **Final completion:** 2009-12
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2009-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00693329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00693329, "Neutrophil Gelatinase-associated Lipcalin(NGAL): A Novel Blood Marker for Determining the Risk of Developing Contrast-Induced Nephopathy". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00693329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*